10.24.11
Norwich Pharmaceuticals is expanding its pilot scale production capabilities at its Norwich, NY facility. The expansion will double current capacity for pilot scale development and manufacturing and includes equipment, surface area and staff.
“We’re providing a world class experience for customers seeking product development and pilot scale manufacturing services,” said Terry Novak, president of Norwich Pharmaceuticals. “Through this significant capital investment, Norwich is not only adding production capacity, we also are strengthening project management, increasing on-time delivery and further expanding our capability to provide customers with one comprehensive solution for all stages of the product lifecycle.”
Development and pilot scale facilities include 12,000 sq. ft. of dedicated space with DEA, solvent and potent compound capabilities, including two analytical labs dedicated to support R&D and GMP development projects. The facilities, instrumentation and technology are designed to complement the company’s commercial capabilities, allowing direct transfer from analytical services to quality control, enabling a fast track to trade production.
“This expansion provides the flexibility to run multiple projects simultaneously,” said Robert O’Connor, Ph.D., vice president, product development and technical services, Norwich Pharmaceuticals. “With the additional GMP processing rooms and newly installed equipment, Norwich is able to provide greater capacity for solvent high shear granulation, fluid bed granulation, drying, column coating, and tablet coating.”
The project will be completed early next year and includes the installation of a 300L Collette Gral high shear granulator with solvent capability, GEA/Niro 2/3 fluid bed granulator/dryer with solvent capability, GEA/Niro 4/5 fluid bed granulator/dryer with solvent capability, O’Hara 24/36” Labcoat III coating pan with solvent capability, and MG Planeta Encapsulator with dual pellet feeders.
Staffing additions are also underway to support the increased plant capacity and broaden the engineering capabilities offered through Norwich product development and technical services.
“We’re providing a world class experience for customers seeking product development and pilot scale manufacturing services,” said Terry Novak, president of Norwich Pharmaceuticals. “Through this significant capital investment, Norwich is not only adding production capacity, we also are strengthening project management, increasing on-time delivery and further expanding our capability to provide customers with one comprehensive solution for all stages of the product lifecycle.”
Development and pilot scale facilities include 12,000 sq. ft. of dedicated space with DEA, solvent and potent compound capabilities, including two analytical labs dedicated to support R&D and GMP development projects. The facilities, instrumentation and technology are designed to complement the company’s commercial capabilities, allowing direct transfer from analytical services to quality control, enabling a fast track to trade production.
“This expansion provides the flexibility to run multiple projects simultaneously,” said Robert O’Connor, Ph.D., vice president, product development and technical services, Norwich Pharmaceuticals. “With the additional GMP processing rooms and newly installed equipment, Norwich is able to provide greater capacity for solvent high shear granulation, fluid bed granulation, drying, column coating, and tablet coating.”
The project will be completed early next year and includes the installation of a 300L Collette Gral high shear granulator with solvent capability, GEA/Niro 2/3 fluid bed granulator/dryer with solvent capability, GEA/Niro 4/5 fluid bed granulator/dryer with solvent capability, O’Hara 24/36” Labcoat III coating pan with solvent capability, and MG Planeta Encapsulator with dual pellet feeders.
Staffing additions are also underway to support the increased plant capacity and broaden the engineering capabilities offered through Norwich product development and technical services.